Selected article for: "additional analysis and long term follow"

Author: Price, Angeline; Barlow-Pay, Fenella; Duffy, Siobhan; Pearce, Lyndsay; Vilches-Moraga, Arturo; Moug, Susan; Quinn, Terry; Stechman, Michael; Braude, Philip; Mitchell, Emma; Myint, Phyo Kyaw; Verduri, Alessia; McCarthy, Kathryn; Carter, Ben; Hewitt, Jonathan
Title: Study protocol for the COPE study: COVID-19 in Older PEople: the influence of frailty and multimorbidity on survival. A multicentre, European observational study
  • Cord-id: 4tmxlm4r
  • Document date: 2020_9_29
  • ID: 4tmxlm4r
    Snippet: INTRODUCTION: This protocol describes an observational study which set out to assess whether frailty and/or multimorbidity correlates with short-term and medium-term outcomes in patients diagnosed with COVID-19 in a European, multicentre setting. METHODS AND ANALYSIS: Over a 3-month period we aim to recruit a minimum of 500 patients across 10 hospital sites, collecting baseline data including: patient demographics; presence of comorbidities; relevant blood tests on admission; prescription of ACE
    Document: INTRODUCTION: This protocol describes an observational study which set out to assess whether frailty and/or multimorbidity correlates with short-term and medium-term outcomes in patients diagnosed with COVID-19 in a European, multicentre setting. METHODS AND ANALYSIS: Over a 3-month period we aim to recruit a minimum of 500 patients across 10 hospital sites, collecting baseline data including: patient demographics; presence of comorbidities; relevant blood tests on admission; prescription of ACE inhibitors/angiotensin receptor blockers/non-steroidal anti-inflammatory drugs/immunosuppressants; smoking status; Clinical Frailty Score (CFS); length of hospital stay; mortality and readmission. All patients receiving inpatient hospital care >18 years who receive a diagnosis of COVID-19 are eligible for inclusion. Long-term follow-up at 6 and 12 months is planned. This will assess frailty, quality of life and medical complications. Our primary analysis will be short-term and long-term mortality by CFS, adjusted for age (18–64, 65–80 and >80) and gender. We will carry out a secondary analysis of the primary outcome by including additional clinical mediators which are determined statistically important using a likelihood ratio test. All analyses will be presented as crude and adjusted HR and OR with associated 95% CIs and p values. ETHICS AND DISSEMINATION: This study has been registered, reviewed and approved by the following: Health Research Authority (20/HRA1898); Ethics Committee of Hospital Policlinico Modena, Italy (369/2020/OSS/AOUMO); Health and Care Research Permissions Service, Wales; and NHS Research Scotland Permissions Co-ordinating Centre, Scotland. All participating units obtained approval from their local Research and Development department consistent with the guidance from their relevant national organisation. Data will be reported as a whole cohort. This project will be submitted for presentation at a national or international surgical and geriatric conference. Manuscript(s) will be prepared following the close of the project.

    Search related documents:
    Co phrase search for related documents
    • accountability insurance portability act and local approval: 1
    • accountability insurance portability and action mechanism: 1
    • accountability insurance portability and local approval: 1
    • ace inhibitor and acei ace inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ace inhibitor and action mechanism: 1, 2, 3, 4
    • action mechanism and local approval: 1